Status:

NOT_YET_RECRUITING

Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis

Lead Sponsor:

Changchun GeneScience Pharmaceutical Co., Ltd.

Collaborating Sponsors:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions:

Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity

Untreated With Systemic Therapy

Eligibility:

All Genders

18-85 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of nanocrystalline medroxyprogesterone acetate for improving appetite and weight gain patients with non-small cell lung cancer (NSCLC) ...

Eligibility Criteria

Inclusion

  • ≥18 years at the time of enrollment.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  • Life expectancy ≥6 months.
  • Histologically or cytologically confirmed metastatic (stage IV) driver gene-negative non-squamous non-small cell lung cancer (NSCLC) that is unresectable and not amenable to curative therapy
  • Subjects with no prior systemic chemotherapy for metastatic non-small cell lung cancer (NSCLC).

Exclusion

  • Presence of any gastrointestinal absorption-impairing conditions (e.g., dysphagia, malabsorption, prior gastrectomy, or uncontrolled vomiting); current use of tube feeding/parenteral nutrition; or existence of anorexia nervosa, psychiatric disorder-induced anorexia, or pain-related feeding intolerance.
  • Driver gene-positive NSCLC or histologically/cytologically confirmed squamous cell-dominant NSCLC.
  • Patients with Cushing's syndrome, adrenal/pituitary insufficiency; poorly controlled diabetes mellitus.
  • Concurrent enrollment in another clinical trial, unless it is an observational/non-interventional study or the follow-up phase of an interventional trial.

Key Trial Info

Start Date :

June 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2027

Estimated Enrollment :

174 Patients enrolled

Trial Details

Trial ID

NCT06961188

Start Date

June 1 2025

End Date

December 31 2027

Last Update

May 7 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China, 430000

Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis | DecenTrialz